Opportunities To Accelerate Allogeneic Cell Therapy

Cell therapies (CTs) are revolutionizing patient care and enabling treatment for serious or life-threatening diseases. While autologous CT will remain the go-to solution in the near term for development of personalized cancer therapeutics, access to treatment is restricted due to inefficient manufacturing and distribution processes, as well as high costs.

Allogeneic CTs are emerging as a viable option to expand access to personalized medicine and treat a wider patient population with increased speed. Allogeneic CTs are engineered for specific therapeutic applications in any patient, and can be produced uniformly, at scale, in a quality-controlled environment. This “off-the-shelf” approach streamlines production processes and allows pharmaceutical companies to manufacture therapies in larger batches.

However, allogeneic CTs still face a number of obstacles that stand in the way of widespread adoption. Overcoming the possibility of adverse immune responses and achieving consistent quality results from one batch of cells to another is necessary to ensure patient safety and product efficacy. Learn more about the potential of allogeneic CTs to combine the efficacy of personalized medicine with the scalability, accessibility, and uniformity of traditional off-the-shelf therapeutics.